comprehensive -WSS

comprehensive

author：explore 2025-10-01 02:16:29 - browse：99

Sammy Kimball for STAT

Can Novavax finally get it right? What’s a “triple-G” drug? And is Novo Nordisk losing ground?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Elaine Chen joins us to explain how the era of Wegovy could be short-lived in light of powerful new weight-loss medicines from Eli Lilly. Then, John Jacobs, the new CEO of Novavax, stops by to explain his plan to right the ship at a company that has struggled to make the most of its potent Covid-19 vaccine.

For more on what we cover, here’s the news on Lilly; here’s more on Novavax; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Medical records are filled with copy
Next article： Readout Newsletter: Beam, Prozac, "TechBio" and more

hotspot

WSS

CDC panel: People 65 and older should get a Covid spring booster shot

Elisabeth Bik tackles the widespread issue of research misconduct

NEJM study measures Covid brain fog, impact on IQ

Children’s Hospital revives plan for pedestrian bridge

Novo Nordisk obesity pill bests Wegovy in early trial

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

knowledge

comprehensive

focus

Anesthesiologist group: stop taking Ozempic before surgery

Change Healthcare cyberattack prompts Medicare loan program

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Childhood vaccination ad campaign launches in the U.K.

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Anesthesiologist group: stop taking Ozempic before surgery

Childhood vaccination ad campaign launches in the U.K.

Psychedelics group wrestles with new pharma identity

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

explore

Readout Newsletter: Beam, Prozac, "TechBio" and more

Redefining sustainability for the pharmaceutical industry

Air quality improving but still lags in Black, Hispanic communities

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Elisabeth Bik tackles the widespread issue of research misconduct

hotspot

hotspot

hotspot

knowledge